MASH - Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials

11 recruiting

MASH - Metabolic Dysfunction-Associated Steatohepatitis Trials at a Glance

11 actively recruiting trials for mash - metabolic dysfunction-associated steatohepatitis are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in London, Houston, and Chicago. Lead sponsors running mash - metabolic dysfunction-associated steatohepatitis studies include Madrigal Pharmaceuticals, Inc., E-Scopics, and Akero Therapeutics, Inc.

Browse mash - metabolic dysfunction-associated steatohepatitis trials by phase

Treatments under study

About MASH - Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials

Looking for clinical trials for MASH - Metabolic Dysfunction-Associated Steatohepatitis? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MASH - Metabolic Dysfunction-Associated Steatohepatitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MASH - Metabolic Dysfunction-Associated Steatohepatitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Madrigal Pharmaceuticals, Inc.120 enrolled15 locationsNCT07335601
Recruiting
Phase 3

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled318 locationsNCT06528314
Recruiting

Rezdiffra Pregnancy and Lactation Registry

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Madrigal Pharmaceuticals, Inc.10 enrolled1 locationNCT07541469
Recruiting
Phase 1Phase 2

Study of TGM-312-SC01 in Healthy Participants and Adults With MASH

Healthy ParticipantsMASH - Metabolic Dysfunction-Associated Steatohepatitis
Tangram Therapeutics Plc99 enrolled1 locationNCT07427680
Recruiting
Phase 2

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rivus Pharmaceuticals, Inc.180 enrolled33 locationsNCT07491458
Recruiting

High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Shanghai East Hospital100 enrolled1 locationNCT07463287
Recruiting
Phase 4

Resmiterom Efficacy & Safety in Patients With MASH

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Nabiqasim Industries (Pvt) Ltd165 enrolled1 locationNCT07249788
Recruiting
Phase 2

Digoxin In NASH (CODIN)

MASH - Metabolic Dysfunction-Associated SteatohepatitisNAFLDNASH
Yale University144 enrolled2 locationsNCT06588699
Recruiting
Not Applicable

Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients

MASLDMASH - Metabolic Dysfunction-Associated SteatohepatitisNAFLD+4 more
E-Scopics120 enrolled3 locationsNCT06661655
Recruiting
Not Applicable

To Test Whether Time-restricted Eating Coupled With a Healthy Diet is Beneficial in Liver Cancer Patients

Obesity and OverweightLiver Cancer, AdultMASH - Metabolic Dysfunction-Associated Steatohepatitis
University of California, San Diego50 enrolled1 locationNCT06824974
Recruiting
Not Applicable

Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)

MASH - Metabolic Dysfunction-Associated SteatohepatitisSteatosis of LiverMASH With Fibrosis
Queen Mary University of London72 enrolled2 locationsNCT07013916